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AbstrACt
Objective To undertake a cost-utility analysis of a 
motivational multicomponent lifestyle-modification 
intervention in a community setting (the Healthy Eating 
Lifestyle Programme (HELP)) compared with enhanced 
standard care.
Design Cost-utility analysis alongside a randomised 
controlled trial.
setting Community settings in Greater London, England.
Participants 174 young people with obesity aged 12–19 
years.
Interventions Intervention participants received 12 one-
to-one sessions across 6 months, addressing lifestyle 
behaviours and focusing on motivation to change and self-
esteem rather than weight change, delivered by trained 
graduate health workers in community settings. Control 
participants received a single 1-hour one-to-one nurse-
delivered session providing didactic weight-management 
advice.
Main outcome measures Mean costs and quality-
adjusted life years (QALYs) per participant over a 1-year 
period using resource use data and utility values collected 
during the trial. Incremental cost-effectiveness ratio (ICER) 
was calculated and non-parametric bootstrapping was 
conducted to generate a cost-effectiveness acceptability 
curve (CEAC).
results Mean intervention costs per participant were 
£918 for HELP and £68 for enhanced standard care. 
There were no significant differences between the two 
groups in mean resource use per participant for any type 
of healthcare contact. Adjusted costs were significantly 
higher in the intervention group (mean incremental costs 
for HELP vs enhanced standard care £1003 (95% CI £837 
to £1168)). There were no differences in adjusted QALYs 
between groups (mean QALYs gained 0.008 (95% CI 
−0.031 to 0.046)). The ICER of the HELP versus enhanced 
standard care was £120 630 per QALY gained. The CEAC 
shows that the probability that HELP was cost-effective 
relative to the enhanced standard care was 0.002 or 
0.046, at a threshold of £20 000 or £30 000 per QALY 
gained.
Conclusions We did not find evidence that HELP was 
more effective than a single educational session in 
improving quality of life in a sample of adolescents with 
obesity. HELP was associated with higher costs, mainly 
due to the extra costs of delivering the intervention and 
therefore is not cost-effective.
trial registration number ISRCTN99840111.
IntrODuCtIOn 
Obesity is associated with significant health 
expenditures. In England, the costs of over-
weight and obesity to the health system 
have been calculated to be £4.2 billion per 
annum.1 Individuals with obesity have been 
found to have medical costs approximately 
30% greater than their normal-weight peers.2 
In terms of non-health care costs, productivity 
losses due to obesity have been estimated to 
strengths and limitations of this study
 ► This study was based on data from a randomised 
controlled trial.
 ► The economic evaluation followed published 
best-practice guidance.
 ► Intervention costs were calculated as mean values 
per participant and did not include participant-level 
variation.
 ► Resource use data were collected retrospectively 
from study participants and may be affected by in-
accurate recall.
 ► Intervention costs were relatively high due to the 
large number of providers involved, producing a 
small number of participants per provider.
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be £15.8 billion.1 Childhood obesity in particular imposes 
a substantial cost to the health system, with estimates of 
around US$14 billion per annum in the USA.3 
Obesity in children and adolescents is a global public 
health concern. Approximately 7% of children and 
adolescents in the UK have obesity at a level likely to be 
associated with comorbidities.4
Prevention of obesity is important, so too are effec-
tive treatments for those already affected. Lifestyle 
interventions, involving a combination of diet, exercise 
and/or behaviour modification are essential for obesity 
management.5
The Healthy Eating and Lifestyle Programme (HELP) 
is a community-delivered evidence-based multicompo-
nent intervention focusing on enhancing motivation to 
change, developing self-efficacy and self-esteem for indi-
viduals with obesity aged 12–19 years, seeking help to 
manage their weight. In an accompanying paper,6 we eval-
uated the efficacy of HELP intervention compared with 
enhanced standard care for adolescents with obesity. In 
this paper, we focus on the cost-effectiveness of the HELP 
intervention.
There are few economic evaluations of childhood 
lifestyle obesity interventions; and among those that 
have been conducted, differences in the type of inter-
vention, age of participants, cost components included, 
country of setting, outcomes of interest and methodol-
ogies mean that it is difficult to draw conclusions as to 
whether such interventions are cost-effective (see online 
supplementary table 1).
Therefore, the aim of this paper was to assess the costs 
and cost-effectiveness of the HELP intervention from the 
perspective of the UK National Health Service (NHS).
MethODs
trial design
The HELP trial was a Medical Research Council complex 
phase III efficacy randomised clinical trial. The study 
tested a community-delivered multicomponent interven-
tion designed for adolescents, developed from best prac-
tice as identified by the National Institute for Health and 
Care Excellence (NICE).5
The study population comprised 174 young people 
with obesity (body mass index (BMI) >95th BMI centile 
for age and sex based on the UK 1990 growth refer-
ence7), aged 12–19 years, recruited from primary care 
and community settings within the Greater London area. 
Participants were individually randomised to receiving 
either the HELP intervention (n=87) or enhanced stan-
dard care (n=87).
Intervention participants and at least one parent 
attended 12 fortnightly ~60 min sessions with a Graduate 
Health Worker (‘provider’) in one-to-one meetings over 
6 months. A written manual was used to enable delivery 
in a standardised manner by all the providers. The inter-
vention comprised motivational interviewing and solu-
tion-focused approaches to increase engagement and 
concordance with the four programme components: (1) 
modifying eating behaviour and encouraging regular 
eating patterns, (2) decreasing sedentary behaviour and 
increasing lifestyle and programme activity, (3) reducing 
intake of energy-dense foods and increasing healthy 
nutritional choice and (4) addressing emotional eating 
triggers.
Controls attended one one-to-one enhanced standard 
care session delivered by a community or primary care 
nurse at the young person’s general practice or an alter-
native community setting. Where a practice nurse was not 
available, a trained staff (eg, agency nurse, healthcare 
assistant) was provided by the study team to deliver the 
session. The session lasted ~40–60 min and incorporated 
standard Department of Health guidance and published 
information on obesity including information on eating 
behaviours, healthy activity levels and healthy eating 
patterns.
Further details of the structure of the clinical trial are 
available from the study protocol8 and from the accompa-
nying paper.6
The trial found that mean BMI across the whole study 
population was 32.3 kg/m2 (SD 4.4) at the start and 
32.6 kg/m2 (SD 4.7) at the end of the intervention. There 
were no significant differences in the primary outcome, 
BMI at 6 months, between groups: adjusted difference in 
BMI −0.11 kg/m2 ((95% CI −0.62 to 0.40), P value=0.7). 
No significant differences were observed for changes 
in secondary outcomes including BMI z-score, fat mass, 
self-esteem, eating behaviours or quality of life (all P 
values >0.3) between intervention and control groups at 
6 months.6 The process evaluation showed that partici-
pants and their families found the intervention highly 
engaging, respectful and helpful in making reported 
behavioural changes.
Patient involvement
Adolescents and their families were not involved in the 
design of the study; however, conversations with families 
about questionnaires had taken place in relation to other 
projects and audits. Feedback from clinical contact with 
adolescents and parents were used to inform the devel-
opment of the research question and outcome measures. 
Adolescents and parents were not involved in the recruit-
ment and conduct of the study. As part of the study, an 
integrated process evaluation reviewed participants’ 
experience of taking part in the randomised controlled 
trial. In addition, an independent qualitative evaluation 
of participant experience was completed and presented 
at a dissemination day. Adolescents and parents partici-
pated in the dissemination day contributing to a future 
research design. A summary of the study results was sent 
to all adolescents who took part in the trial.
Overview of economic evaluation
We undertook a cost-utility analysis to compare the costs 
and outcomes associated with HELP versus enhanced 
standard care. The outcome measure was quality-adjusted 
3Panca M, et al. BMJ Open 2018;8:e018640. doi:10.1136/bmjopen-2017-018640
Open access
life years (QALYs), which combine length of life and 
quality of life and is consistent with the NICE recommen-
dations.9 The analysis took a UK NHS perspective; costs 
from a personal social services perspective were likely to 
be negligible and so were excluded. Costs were calculated 
in 2013/2014 UK pounds. The time horizon was 1 year, 
reflecting follow-up in the trial. Extrapolation beyond 
the end of the trial using decision-analytical modelling 
was not undertaken because the within-trial analysis 
found no evidence of significant differences in benefits 
between intervention and control groups, and costs were 
significantly higher in the intervention group; the 1 year 
time horizon was long enough to reflect all important 
differences in costs or outcomes between the two treat-
ments. Since the time horizon was 1 year, discounting was 
unnecessary.
resource use and costs
For every participant, we calculated the cost of the life-
style intervention and the cost of follow-up using resource 
use data collected retrospectively in the trial via ques-
tionnaires sent to participants at baseline and 6 and 12 
months postrandomisation.
The cost of HELP included providers’ training, learning 
materials for providers and participants and time spent 
by providers/experienced psychologist in each follow-up 
session with participants.
There were 21 providers who received training to deliver 
HELP (each trained for 5 days; 7 hours/day) from experi-
enced psychologists in specific motivational interviewing 
techniques and the use of solution-focused questioning 
in the intervention group. In the enhanced standard care 
group, the nurses did not receive any training in delivery 
style.
In the HELP group, we accounted for 1.5 hours spent 
by the provider to deliver the intervention and room 
rental for each session, plus 1.5 hours spent by the expe-
rienced psychologist to supervise the delivery of session 
1 of the intervention with the provider’s first participant. 
In the enhanced standard care group, we accounted for 
1 hour spent by the nurse to deliver the single educational 
session plus room rental.
Providers’ travel time (mean 1.5 hours) to and from 
session venues, and travel costs were accounted for in the 
HELP group. Travel time (mean 2 hours) to and from 
session venues was accounted for in the enhanced stan-
dard care group only if the intervention was delivered by 
a nurse provided by the study team (n=36), as other stan-
dard care sessions were provided by local practice nurses 
in their own practice.
Educational materials (manuals/leaflets) were supplied 
for both providers and participants in the HELP group. 
Leaflets were supplied for participants in the enhanced 
standard care group.
Follow-up resource use included: general practitioner 
(GP) surgery consultations; GP telephone consulta-
tions; GP home consultations; contacts with the practice 
nurse; referrals to secondary care services (eg, dietitian, 
physiotherapist, osteopath, chiropractor, psychologist, 
counsellor, dentist, radiologist, community pharmacist); 
hospital inpatient admissions; hospital day cases and 
hospital outpatient visits.
Unit costs were obtained from published sources10 11 
(for all resource use associated with follow-up care not 
directly related to the interventions; table 1) and local 
costs (for any resource use needed to deliver the interven-
tion; see online supplementary table 2), inflated where 
appropriate.
utilities and QALYs
Participants’ generic health state was assessed using the 
EuroQol 5D (EQ-5D-3L) descriptive system12 13 at base-
line, 6 and 12 months postrandomisation. The EQ-5D-3L 
is a validated generic health-related preference-based 
measure comprising five dimensions (mobility, self-care, 
usual activities, pain, anxiety/depression) with three 
levels in each item. Every EQ-5D-3L health state was 
converted into a single summary index (utility value) 
using a formula that attaches weights to each of the levels 
in each dimension based on valuations by general popu-
lation samples. Given the perspective of our analysis, 
we used a value set for the UK population to calculate 
utility values at each time point for every participant.14 
Utility values at each point in time were calculated. The 
values lie on a scale between 0 (equivalent to death) and 
1 (equivalent to full health); negative values are possible, 
representing states worse than death. A utility profile 
was created for each participant assuming a straight line 
relation between their utility values at each measurement 
point in time. QALYs for each participant from baseline 
to 12 months were calculated as the area under the utility 
profile.
Dealing with missing data
Multiple imputation was used to impute missing data for 
costs of primary and secondary care contacts, total cost, 
utility values at every time point and total QALYs. The cost 
variables were unit costs multiplied by resource use. Age, 
gender and treatment allocation were included in the 
imputation models as additional explanatory variables.
We used multiple imputation with chained equations to 
impute missing data under the assumptions that data were 
missing at random. We generated 20 imputed datasets.
statistical methods
Mean resource use, costs, utility values and QALYs were 
compared between groups on an intention-to-treat basis 
and the incremental cost-effectiveness ratio (ICER) 
calculated.
We calculated differences in mean costs and QALYs 
between groups using regression analysis, regressing indi-
vidual QALYs and costs against treatment allocation in 
the trial controlling for other factors.
QALYs gained were adjusted for age, gender and base-
line utility values. Incremental costs were adjusted for age, 
gender and costs in the 6-month period prior to baseline. 
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To analyse QALYs gained, we used a linear regression 
model. To account for skewness of the cost data, we used 
a generalised linear model with gamma family and log 
link;15 we also considered using log Normal, Gaussian, 
inverse Gaussian and negative binomial distributions, but 
the gamma model gave the best fit in terms of residual 
plots and the Akaike Information Criterion. Standard 
errors were corrected to account for uncertainty in 
the imputed values. Analyses were carried out using 
STATA V.13.1.
The ICER was calculated by dividing the incremental 
costs (difference in costs between HELP intervention and 
enhanced standard care groups) by incremental QALYs 
(difference in QALYs between HELP intervention and 
enhanced standard care groups). We used the cost-ef-
fectiveness threshold range recommended by NICE 
(£20 000 to £30 000)9 as the lower and upper limits of the 
maximum willingness to pay for a QALY.
For each of the 20 imputed datasets, we ran 1000 
bootstrap replications and combined the results using 
published equations16 to calculate standard errors around 
mean values accounting for uncertainty in imputed values, 
the skewed nature of the cost data and utility values and 
sampling variation. Standard errors were used to calcu-
late 95% CIs around point estimates.
A cost-effectiveness acceptability curve17 showing the 
probability that the HELP intervention was cost-effective 
compared with enhanced standard care at a range of 
values for the maximum willingness to pay for a QALY 
was generated based on the proportion of the bootstrap 
replications across all 20 imputed datasets. The proba-
bilities that the HELP intervention was cost-effective at a 
maximum willingness to pay for a QALY of £20 000 and 
£30 000 were reported.
resuLts
Participants’ characteristics
Participants in the clinical trial were well balanced in 
terms of age, gender and baseline BMI and EQ-5D values, 
although there were slightly fewer black participants and 
slightly greater numbers of white and Asian participants 
in the HELP arm.6
resource use and costs
During the 12-month follow-up, there were no significant 
differences in any component of healthcare resource use 
between HELP and enhanced standard care (table 1). 
The most common types of contact were GP surgery visits 
for both groups with a mean (SD) of 1.57 (SD 2.31) visits 
per participant in the HELP group (n=58) and 1.46 (SD 
1.80) visits per participant in the enhanced standard care 
group (n=50), followed by outpatient visits in the HELP 
group (mean 0.64 (SD 1.22), n=58) and counsellor visits 
Table 1 Mean healthcare resource use±SD, unit costs (2013/2014 values), complete data
Type of resource use (unit)
Unit costs
(references)
HELP
Enhanced standard 
care
Difference P valueN Mean±SD N Mean±SD
Hospital inpatient (admission) £1758.369 59 0.05±0.29 53 0.06±0.41 −0.01 0.93
Hospital day case (attendance) £693.009 59 0.15±0.81 52 0.04±0.19 0.11 0.32
Hospital outpatient (visit) £108.229 58 0.64±1.22 52 0.29±0.70 0.35 0.07
A&E (visits) £115.009 58 0.29±0.56 53 0.23±0.54 0.07 0.53
GP surgery (consultation) £45.0010 58 1.57±2.31 50 1.46±1.80 0.11 0.79
GP home (visit) £114.0010 59 0.00±0.00 53 0.00±0.00 0.00 0.00
GP phone (consultation) £27.0010 59 0.27±0.69 53 0.32±0.94 −0.05 0.75
Nurse home (visit) £70.0010 59 0.02±0.13 52 0.00±0.00 0.02 0.35
Nurse surgery (visit) £13.4310 58 0.26±0.78 53 0.25±0.78 0.01 0.93
Nurse phone (consultation) £13.4310 58 0.02±0.13 52 0.00±0.00 0.02 0.35
NHS dietician (visit) £35.0010 58 0.09±0.34 52 0.04±0.19 0.05 0.37
Community pharmacist (contact) £56.0010 58 0.31±0.78 52 0.15±0.54 0.16 0.23
NHS physiotherapist (visit) £34.0010 58 0.14±0.71 53 0.19±1.00 −0.05 0.76
Private physiotherapist (visit) £77.0010 58 0.03±0.26 53 0.06±0.41 −0.02 0.73
Osteopath (visit) £34.0010 58 0.03±0.26 53 0.00±0.00 0.03 0.34
Chiropractor (visit) £34.0010 58 0.00±0.00 53 0.00±0.00 0.00 0.00
Psychologist (visit) £59.0010 58 0.31±1.88 53 0.06±0.41 0.25 0.34
Counsellor (visit) £58.0010 58 0.09±0.66 53 0.30±1.48 −0.22 0.31
Any other healthcare (contact) £81.009 10 57 0.46±1.31 53 0.45±1.25 0.01 0.99
A&E, accident and emergency; GP, general practitioner; HELP,  Healthy Eating and Lifestyle Programme; NHS, National Health Service. 
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in the enhanced standard care group (mean 0.30 (SD 
1.48), n=53). Any other healthcare visits comprised visits 
with a dentist, orthodontist or an optician.
In the complete case analysis, the mean total cost of 
healthcare resource use per participant were £363 (95% 
CI £221 to £505) in the HELP group (n=55) and £357 
(95% CI £114 to £600) in the enhanced standard care 
group (n=48; table 2). Accounting for missing data using 
multiple imputation, the values were £320 (95% CI £212 
to £428) and £462 (95% CI £268 to £657), respectively.
There were 758 sessions delivered in the intervention 
group and 71 sessions delivered in the control group. 
The mean total intervention cost per participant was 
£918 (95% CI £875 to £960) for the delivery of the HELP 
intervention and £68 (95% CI £63 to £73; table 2) for 
enhanced standard care.
Accounting for missing data using multiple imputation 
the mean total costs per participant were £1238 (95% CI 
£1237 to £1452) in the intervention group (n=87) and 
£530 (95% CI £343 to £732) in the control group (n=87; 
table 2). Values for complete case analysis followed the 
same trend (table 2). The difference in intervention costs 
between intervention and control groups was driven by 
the costs of the delivery of HELP intervention and provid-
er’s travel.
utilities and QALYs
Mean utility values per participant at each follow-up point 
were similar for both groups and did not vary significantly 
over time in either group (table 3).
Accounting for missing data, mean utility values per 
participant in the intervention group increased from 
0.792 (95% CI 0.736 to 0.849) at baseline to 0.848 (95% 
CI 0.806 to 0.890) at 6 months and then at 0.849 (95% 
CI 0.807 to 0.891) at 12 months. The mean utility values 
per participant in control group increased from 0.829 
(95% CI 0.788 to 0.870) at baseline to 0.891 (95% CI 
0.858 to 0.924) at 6 months and declined to 0.847 (95% 
CI 0.805 to 0.889) at 12 months. Mean total QALYs per 
participant in the intervention group were 0.855 (95% CI 
0.816 to 0.895) and in control group were 0.881 (95% CI 
0.851 to 0.912). Utility values and QALYs were similar for 
complete cases.
Table 2 Mean cost±SD of HELP and enhanced standard care and resource use per participant
Type of costs HELP
Enhanced standard 
care
HELP versus enhanced 
standard care
Training
  Provider/nurse £130±£0 £0±£0 £130
  Psychologist £46±£0 £0±£0 £46
Intervention
  Provider/nurse £201±£90 £33±£17 £168
  Psychologist £134±£60 £0±£0 £134
  Room rental £114±£51 £13±£6 £101
Travel
  Provider/nurse £279±£124 £22±£26 £257
Materials
  Manual for provider £3±£0 £0±£0 £3
  Manual/leaflets for participant £5±£0 £1±£0 £4
  Other materials for participant £5±£0 £0±£0 £5
Intervention costs per participant £918±£201 £68±£22 £850
Costs (95% CI) of healthcare resource use during follow-up
  Complete cases £363
(£221 to £505)
(n=55)
£357
(£114 to £600)
(n=48)
£6
(-£264 to £275)
(n=103)
  With imputation £320
(£212 to £428)
£462
(£268 to £657)
-£142
(-£363 to £79)
Total costs (95% CI) per participant (intervention cost plus healthcare resource use during follow-up)
  Complete cases £1281
(£1246 to £1527)
(n=55)
£425
(£188 to £675)
(n=48)
£855
(£685 to £1,224)
(n=103)
  With imputation £1238
(£1237 to £1452)
£530
(£343 to £732)
£708
(£587 to £1028)
HELP, Healthy Eating and Lifestyle Programme. 
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Cost-utility analysis
In the base case analysis, accounting for missing data 
using multiple imputation and baseline characteristics, 
there were no significant differences in costs or QALYs 
between the two groups: the mean incremental cost for 
HELP versus enhanced standard care was £1003 (95% CI 
£837 to £1 168) and the mean QALYs gained were 0.008 
(95% CI −0.031 to 0.046) (table 4). The incremental costs 
and QALYs gained for HELP versus enhanced standard 
care remained not significantly different from zero when 
rerunning the base case analysis without adjustment and 
using complete cases.
The ICER of the HELP versus enhanced standard care 
was £120 630 per QALY gained. The cost-effectiveness 
acceptability curve shows that the probability that HELP 
was cost-effective relative to the enhanced standard care 
was 0.002 or 0.046, at a threshold of £20 000 or £30 000 
per QALY gained (figure 1).
DIsCussIOn
Principal findings
The HELP trial showed that changes in BMI in adolescents 
with obesity who received the intervention are similar to 
those seen in adolescents who received enhanced stan-
dard care. Our economic analysis of the HELP trial 
showed that the intervention had similar outcomes but 
higher costs when compared with the enhanced standard 
care. Resource use during follow-up was similar between 
the trial arms, and therefore the cost of the HELP inter-
vention was the major driver of the cost difference.
Given no differences in outcomes or resource use 
during follow-up between groups and higher interven-
tion costs, our findings indicate the HELP intervention is 
unlikely to be cost-effective.
strengths and weaknesses
The HELP intervention was designed specifically for adoles-
cents who have difficulties losing weight and encouraged 
Table 3 Mean utility values and QALYs per participant
Utility values
HELP Enhanced standard care
Mean (95% CI) Mean (95% CI)
Complete cases
  Baseline 0.793 (n=83) (0.735 to 0.850) 0.833 (n=85) (0.792 to 0.875)
  6 months 0.852 (n=68) (0.803 to 0.902) 0.881 (n=63) (0.844 to 0.918)
  12 months 0.851 (n=59) (0.799 to 0.902) 0.871 (n=52) (0.812 to 0.930)
QALYs 0.837 (n=54) (0.787 to 0.887) 0.867 (n=50) (0.828 to 0.907)
With imputation
  Baseline 0.792 (0.736 to 0.849) 0.829 (0.788 to 0.870)
  6 months 0.848 (0.806 to 0.890) 0.891 (0.858 to 0.924)
  12 months 0.849 (0.807 to 0.891) 0.847 (0.805 to 0.889)
QALYs 0.855 (0.816 to 0.895) 0.881 (0.851 to 0.921)
Data include values imputed using multiple imputation (see text).
HELP, Healthy Eating and Lifestyle Programme; QALYs, quality-adjusted life years.
Table 4 Cost-effectiveness of HELP intervention versus enhanced standard care: complete case and imputed data analyses 
(baseline to 12 months)
Incremental cost QALYs gained
Mean (95% CI) Mean (95% CI)
Base case* £1003 (£837 to £1 168) 0.008 (−0.031 to 0.046)
No adjustment† £861 (£713 to £1 010) −0.037 (−0.100 to 0.027)
Complete case analysis‡ £1022 (£673 to £1 372) 0.018 (−0.021 to 0.058)
Complete case analysis with no adjustment§ £955 (£432 to £1 477) −0.030 (−0.093 to 0.033)
*Data include values imputed using multiple imputation with SEs corrected to account for uncertainty in the imputed values. The QALYs 
gained are adjusted for age, gender and baseline utility values. The incremental costs are adjusted for age, gender costs in the 6-month 
period prior to baseline.
†As for the base case analysis except the QALYs gained and the incremental costs are unadjusted.
‡As for the base case analysis except there is no multiple imputation of missing values.
§As for the base case analysis except the QALYs gained and the incremental costs are unadjusted and there is no multiple imputation of 
missing values.
HELP, Healthy Eating and Lifestyle Programme; QALYs, quality-adjusted life years.
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parents to participate and support their children. The 
major strength of the study is that it is based on data from a 
randomised controlled trial and that best practice methods 
have been used in the economic evaluation. Moreover, the 
numbers of control and intervention participants in the 
economic evaluation were balanced and their baseline char-
acteristics were similar, although there were slightly fewer 
black participants and slightly greater numbers of white and 
Asian participants in the HELP arm.
Self-reported questionnaires were used for obtaining 
resource use data; these are a valid method of collecting 
data on healthcare resource use and are commonly used. 
We acknowledge that self-reported questionnaires may be 
subject to inaccurate recall, though we have no reason to 
believe this would be different between groups.
Due to high staff turnover during the study, there were 
21 providers trained to deliver the intervention, and this 
might contribute to the relatively high mean cost per 
participant of the HELP intervention; smaller number of 
providers would lower the average training costs.
Also one-to-one meetings between participants and 
providers potentially made the intervention relatively 
resource intensive. The costs could be reduced if the inter-
vention was provided in a group setting, however, the motiva-
tional interviewing is unlikely to be possible in such a setting.
The HELP intervention was costed using a uniform 
assessment of the time spent by providers in delivering 
the intervention. Although it is expected that there will 
be some variability at individual level, our approach to 
costing the intervention is pragmatic and unlikely to 
affect our findings.
Our economic analysis had a time horizon of only 1 year, 
reflecting the duration of follow-up in the trial. While this 
is a limited duration, given we found no differences in 
utility values, QALYs or resource use during follow-up 
between groups up to 12 months then measuring costs 
and benefits after 1 year using modelling was unlikely to 
change the results.
We also only included NHS costs in our evaluation 
and not, for example, costs to participants and families. 
Given there were no differences in healthcare resource 
use during follow-up and utility values between groups, 
including these costs is unlikely to change our conclu-
sions. They may make the intervention appear less cost-ef-
fective if HELP intervention costs were to increase when 
incorporating time and travel costs borne by adolescents 
and families to participate in the intervention.
Comparisons with other studies
As noted (see online supplementary table 1), there are 
few evaluations of childhood obesity interventions that 
include an economic evaluation with which to compare 
our results; however, differences between studies in terms 
of age of participants, country, components of the inter-
ventions and outcome measures make comparisons with 
other studies difficult.
In our study, possible explanations as to why there was no 
difference in outcomes between study groups may relate 
to the lack of effect of the intervention (it is possible that 
the trial did not provide an adequate test of the interven-
tion, although adequately powered and methodologically 
robust), methodology (slow recruitment, widening the 
age range, dropouts) and population (highly deprived, 
mental health problems at baseline, despite exclusion of 
those known with mental health conditions).6
Figure 1 Cost-effectiveness acceptability curve showing the probability that the HELP intervention is cost-effective compared 
with enhanced standard care over a range of values of the cost-effectiveness threshold. HELP, Healthy Eating and Lifestyle 
Programme.
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Implications
The health risks and healthcare costs associated with 
overweight and obesity are considerable. A public health 
approach to develop lifestyle interventions in adolescents 
should target factors contributing to obesity and barriers 
to lifestyle change at personal, environmental and socio-
economic levels.18
The HELP intervention was no more efficacious than a 
standard care of a single educational session for reducing 
BMI in a community sample of adolescents with obesity. 
This adds to a large literature on negative weight-manage-
ment trials for children and adolescents. Further work to 
understand how weight-management programmes can be 
delivered effectively to young people should be consid-
ered. Such research must also consider the cost implica-
tions of weight-management programmes.
Future research
Future research is needed to identify the most cost-ef-
fective lifestyle intervention for adolescents with obesity, 
including its length and intensity, as well as long-term 
sustainability into adulthood.
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